open access

Vol 14, No 1 (2019)
Review Papers
Published online: 2019-04-10
Get Citation

A new antithrombotic paradigm in the treatment of atherosclerotic diseases Expert group consensus endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy on the place of rivaroxaban in the treatment of stable coronary artery disease or symptomatic peripheral artery disease

Marcin Barylski, Artur Mamcarz, Janusz Siebert, Filip Marcin Szymański, Krystyna Widecka, Beata Wożakowska-Kapłon, Krzysztof Jerzy Filipiak
DOI: 10.5603/FC.2019.0004
·
Folia Cardiologica 2019;14(1):30-45.

open access

Vol 14, No 1 (2019)
Review Papers
Published online: 2019-04-10

Abstract

The need to improve the efficacy of anticoagulant therapy in secondary prevention is indicated by the fact that intensive antiplatelet therapy only partially reduces cardiovascular risk. The results of the COMPASS study provide evidence that additional blocking of coagulation cascade may significantly affect the further prevention of major cardiovascular events in a selected population of patients. The following document is the opinion of an expert group summarising the latest knowledge regarding anticoagulant therapy in stable coronary disease and peripheral artery disease. 

Abstract

The need to improve the efficacy of anticoagulant therapy in secondary prevention is indicated by the fact that intensive antiplatelet therapy only partially reduces cardiovascular risk. The results of the COMPASS study provide evidence that additional blocking of coagulation cascade may significantly affect the further prevention of major cardiovascular events in a selected population of patients. The following document is the opinion of an expert group summarising the latest knowledge regarding anticoagulant therapy in stable coronary disease and peripheral artery disease. 

Get Citation

Keywords

rivaroxaban; acetylsalicylic acid; stable coronary disease; peripheral artery disease; anticoagulant therapy

About this article
Title

A new antithrombotic paradigm in the treatment of atherosclerotic diseases Expert group consensus endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy on the place of rivaroxaban in the treatment of stable coronary artery disease or symptomatic peripheral artery disease

Journal

Folia Cardiologica

Issue

Vol 14, No 1 (2019)

Pages

30-45

Published online

2019-04-10

DOI

10.5603/FC.2019.0004

Bibliographic record

Folia Cardiologica 2019;14(1):30-45.

Keywords

rivaroxaban
acetylsalicylic acid
stable coronary disease
peripheral artery disease
anticoagulant therapy

Authors

Marcin Barylski
Artur Mamcarz
Janusz Siebert
Filip Marcin Szymański
Krystyna Widecka
Beata Wożakowska-Kapłon
Krzysztof Jerzy Filipiak

References (52)
  1. Baigent C, Blackwell L, Collins R, et al. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373(9678): 1849–1860.
  2. Fruchart JC, Sacks F, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008; 102(10 Suppl): 1K–34K.
  3. Ridker PM, Danielson E, Fonseca FAH, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21): 2195–2207.
  4. Ridker PM, Everett BM, Thuren T, et al. CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017; 377(12): 1119–1131.
  5. Olie RH, van der Meijden PEJ, Ten Cate H. The coagulation system in atherothrombosis: implications for new therapeutic strategies. Res Pract Thromb Haemost. 2018; 2(2): 188–198.
  6. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996; 348(9038): 1329–1339.
  7. Bhatt DL, Fox KAA, Hacke W, et al. CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354(16): 1706–1717.
  8. Bonaca MP, Bhatt DL, Cohen M, et al. PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372(19): 1791–1800.
  9. Bousser MG, Amarenco P, Chamorro A, et al. PERFORM Study Investigators. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet. 2011; 377(9782): 2013–2022.
  10. Morrow DA, Braunwald E, Bonaca MP, et al. TRA 2P–TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012; 366(15): 1404–1413.
  11. Rothberg MB, Celestin C, Fiore LD, et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med. 2005; 143(4): 241–250.
  12. Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol. 2003; 41(4): S62–S69.
  13. Mega JL, Braunwald E, Wiviott SD, et al. ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366(1): 9–19.
  14. Sharma M, Hart RG, Smith EE, et al. Rationale, design and baseline characteristics of participants in the cardiovascular outcomes for people using anticoagulation strategies (COMPASS) trial. Can J Cardiol. 2017; 33(8): 1027–1035.
  15. Eikelboom JW, Connolly S, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017; 377(14): 1319–1330.
  16. Connolly SJ, Eikelboom JW, Bosch J, et al. COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018; 391(10117): 205–218.
  17. Anand SS, Bosch J, Eikelboom JW, et al. COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018; 391(10117): 219–229.
  18. Bonaca MP, Bhatt DL, Cohen M, et al. PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372(19): 1791–1800.
  19. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002; 347(13): 969–974.
  20. Anand S, Yusuf S, Xie C, et al. Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007; 357(3): 217–227.
  21. Anand SS, Caron F, Eikelboom JW, et al. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial. J Am Coll Cardiol. 2018; 71(20): 2306–2315.
  22. Bonaca MP, Scirica BM, Creager MA, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation. 2013; 127(14): 1522–9, 1529e1.
  23. Bonaca MP, Gutierrez JA, Creager MA, et al. Acute limb ischemia and outcomes with vorapaxar in patients with peripheral artery disease: results from the trial to assess the effects of vorapaxar in preventing heart attack and stroke in patients with atherosclerosis-thrombolysis in myocardial infarction 50 (TRA2°P-TIMI 50). Circulation. 2016; 133(10): 997–1005.
  24. Bonaca MP, Bhatt DL, Storey RF, et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol. 2016; 67(23): 2719–2728.
  25. Hiatt WR, Fowkes FG, Heizer G, et al. EUCLID Trial Steering Committee and Investigators. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017; 376(1): 32–40.
  26. Capell WH, Bonaca MP, Nehler MR, et al. Rationale and design for the vascular outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). Am Heart J. 2018; 199: 83–91.
  27. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324(7329): 71–86.
  28. Berger JS, Krantz MJ, Kittelson JM, et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009; 301(18): 1909–1919.
  29. Catalano M, Born G, Peto R, et al. Critical Leg Ischaemia Prevention Study (CLIPS) Group. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med. 2007; 261(3): 276–284.
  30. Cacoub PP, Bhatt DL, Steg PG, et al. CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009; 30(2): 192–201.
  31. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med. 1990; 323(3): 147–152.
  32. Rupprecht HJ, Blank R. Clinical pharmacology of direct and indirect factor Xa inhibitors. Drugs. 2010; 70(16): 2153–2170.
  33. Ross R, Ross R. Atherosclerosis — an inflammatory disease. N Engl J Med. 1999; 340(2): 115–126.
  34. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352(16): 1685–1695.
  35. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999; 341(8): 586–592.
  36. Levi M, van der Poll T, Büller HR. Bidirectional relation between inflammation and coagulation. Circulation. 2004; 109(22): 2698–2704.
  37. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005; 131(4): 417–430.
  38. Borensztajn K, Peppelenbosch MP, Spek CA. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol Med. 2008; 14(10): 429–440.
  39. Borissoff JI, Spronk HMH, Heeneman S, et al. Is thrombin a key player in the 'coagulation-atherogenesis' maze? Cardiovasc Res. 2009; 82(3): 392–403.
  40. Spronk HMH, de Jong AM, Crijns HJ, et al. Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants. Cardiovasc Res. 2014; 101(3): 344–351.
  41. Bonaca MP, Creager MA, Olin J, et al. Peripheral revascularization in patients with peripheral artery disease with vorapaxar: insights from the TRA 2°P-TIMI 50 trial. JACC Cardiovasc Interv. 2016; 9(20): 2157–2164.
  42. Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J. 2010; 31(1): 17–28.
  43. Mitchell JR. Prostaglandins in vascular disease: a seminal approach. Br Med J (Clin Res Ed). 1981; 282(6264): 590–594.
  44. Fulcher J, O'Connell R, Voysey M, et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015; 385(9976): 1397–1405.
  45. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016; 388(10059): 2532–2561.
  46. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387(10022): 957–967.
  47. Yusuf S, Sleight P, Pogue J, et al. Heart Outcomes Prevention Evaluation Study Investigators, Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3): 154–160.
  48. Baigent C, Blackwell L, Collins R, et al. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373(9678): 1849–1860.
  49. European Cardiovascular Disease Statistics 2017 edition. www.ehnheart.org. (5.03.2019).
  50. Charakterystyka produktu leczniczego Xarelto 2,5 mg; 7,5 mg, tabletki powlekane.
  51. Montalescot G, Sechtem U, Achenbach S, et al. Task Force Members, ESC Committee for Practice Guidelines, Document Reviewers. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013; 34(38): 2949–3003.
  52. Aboyans V, Ricco JB, Bartelink MLEL, et al. ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018; 39(9): 763–816.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl